Cipla obtains FDA nod for generic Durezol
Durezol had a market value of approximately $106 million for the 12-month period ended June 2021, according to IQVIA.
The Food and Drug Administration has approved Cipla’s difluprednate ophthalmic emulsion 0.05%.
The medication is the generic of Novartis’ Durezol.
It is used for the treatment of inflammation and pain associated with ocular surgery, and for the treatment of endogenous anterior uveitis.
[Read more: Rolling with the punches: Generics firms innovate, expand scope to stay competitive]
Durezol had a market value of approximately $106 million for the 12-month period ended June 2021, according to IQVIA.
Cipla’s product will be available for shipping soon.